PEN logo

Penumbra Inc. (PEN)

$339.20

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on PEN

Market cap

$13.28B

EPS

4.2

P/E ratio

80.8

Price to sales

9.96

Dividend yield

--

Beta

0.814123

Price on PEN

Previous close

$339.36

Today's open

$339.53

Day's range

$339.08 - $340.86

52 week range

$221.26 - $362.41

Profile about PEN

CEO

Adam Elsesser

Employees

4500

Headquarters

Alameda, CA

Exchange

New York Stock Exchange

Shares outstanding

39162177

Issue type

Common Stock

PEN industries and sectors

Healthcare

Medical Equipment & Supplies

News on PEN

CLPBY or PEN: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Instruments stocks have likely encountered both Coloplast A/S Sponsored ADR (CLPBY) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?

news source

Zacks Investment Research • 8 hours ago

news preview

Allspring Growth Fund Q4 2025 Fund Performers And Detractors

Carpenter Technology Corp. multiple long-term contracts were repriced favorably as airlines keep aging fleets in service longer driving higher maintenance needs. Natera, Inc. doubled the number of oncology sales representatives to drive awareness and volumes in 2026. Natera, Inc. doubled the number of oncology sales representatives to drive awareness and volumes in 2026.

news source

Seeking Alpha • Feb 13, 2026

news preview

Boston Scientific announces results for fourth quarter and full year 2025

MARLBOROUGH, Mass., Feb. 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational1 basis and 12.7 percent on an organic2 basis, all compared to the prior year period.

news source

PRNewsWire • Feb 4, 2026

news preview

GMED vs. PEN: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Penumbra (PEN). But which of these two stocks is more attractive to value investors?

news source

Zacks Investment Research • Feb 3, 2026

news preview

Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm as there may be limited time to enforce your rights Shareholders should contact the firm as there may be limited time to enforce your rights

news source

GlobeNewsWire • Jan 27, 2026

news preview

Artisan Small Cap Fund Q4 2025 Portfolio Activity

During the quarter, we initiated new positions in nLIGHT, Guardant Health and Cellebrite. We also added to Bruker, Hexcel and Penumbra during the quarter. Along with Insmed, we also ended our investment campaigns in Integer Holdings and SharkNinja during the quarter.

news source

Seeking Alpha • Jan 23, 2026

news preview

Penumbra (PEN) Moves 11.8% Higher: Will This Strength Last?

Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

news source

Zacks Investment Research • Jan 16, 2026

news preview

Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc. - PEN

NEW YORK and NEW ORLEANS, Jan. 16, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

news source

PRNewsWire • Jan 16, 2026

news preview

Boston Scientific to buy Penumbra in deal valued at $14.5 billion

Boston Scientific said on Thursday it will buy Penumbra in a deal valued at about $14.5 billion.

news source

Reuters • Jan 15, 2026

news preview

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Penumbra, Inc. (NYSE: PEN)

NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Penumbra, Inc. (NYSE: PEN) related to its sale to Boston Scientific Corporation.

news source

PRNewsWire • Jan 15, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Penumbra Inc.

Open an M1 investment account to buy and sell Penumbra Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in PEN on M1